Madrigalв Dip Apr 2026

Madrigal continues to report positive results from its own clinical trials, including the trial.

: Analysts at Piper Sandler recently raised their price target for Madrigal to $400 (up from $336), viewing the competitor data as validation for the entire MASH treatment market rather than a threat. MadrigalВ Dip

Investment firms, including and Piper Sandler , maintain a bullish outlook despite the price drop: Madrigal continues to report positive results from its

: Following this news, Madrigal shares traded down roughly 5% . Investment Sentiment including and Piper Sandler

The consensus among firms like TipRanks is that Madrigal’s treatment could become a "blockbuster," supported by its first-mover advantage in the space.